The U.S. Food and Drug Administration has cleared the ovarian cancer drug Lynparza to treat advanced pancreatic cancer, according to AstraZeneca and Merck, the companies that developed it.
The U.S. Food and Drug Administration has cleared the ovarian cancer drug Lynparza to treat advanced pancreatic cancer, according to AstraZeneca and Merck, the companies that developed it.
Why pancreatic cancer is such a killer, and what's being done about it. By Mary Brophy Marcus June 20, 2017 / 10:08 AM / CBS News
The approval for Spark Therapeutics offers a life-changing intervention for a small group of patients with a vision-destroying genetic mutation and hope for many more people with other inherited ...
Blood test holds promise for earlier pancreatic cancer detection. By Mary Brophy Marcus July 12, 2017 / 3:58 PM / CBS News
Abbvie, based in North Chicago, Illinois, said Mavyret's list price without insurance will be $26,400 for eight weeks' treatment, $39,600 for 12 weeks' treatment and $52,800 for 16 weeks' treatment.
British drugmaker GW Pharmaceuticals studied the drug in more than 500 children and adults with hard-to-treat seizures, overcoming numerous legal hurdles that have long stymied research into cannabis.
Drugmaker Abbvie said the Food and Drug Administration approved the drug, Orilissa, for pain during menstruation and intercourse and at other times. Abbvie says it's the first new pill for ...
Approved in 2004, Lyrica is Pfizer's second best-selling drug, with sales last year totaling $4.6 billion. The heavily advertised drug costs about $460 to $720 per month without insurance, with ...
Cancer patients, brace yourselves. Many new drug treatments cost nearly $100,000 a year, sparking fresh debate about how much a few months more of life is worth.
The warning is significant because it raps Sanofi for distributing a clinical study that used secondary, not primary, endpoints. ... the superiority analysis of the primary endpoint (e.g ...
The FDA warned Sanofi-Aventis to stop claiming that its breast cancer drug Taxotere is superior to Bristol-Myers Squibb's Taxol. The warning is significant because it raps Sanofi for distributing ...
Completely revised and updated, the Physicians' Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field.
Big Pharma loses key ruling over cancer drug patent. April 1, 2013 / 7:28 AM / AP ... a lawyer for the Indian generic drug manufacturer Cipla, which makes a generic version of Glivec. ...
Certificates available for allergens, aflatoxins, BSE/TSE, Halal, Kosher.
A drug called Xeloda can extend the lives of some women whose breast cancer is not wiped out by standard treatment, a new clinical trial finds.
5 Jun 2018 ... O'Neil DS, Keating NL, Dusengimana JMV, Hategekimana V, ... VH, JMVD, TM, LS and ST; Data collection: VH, JMVD, TM, IN, TF, and LP; Data ...
15 Jan 2020 ... By the present suit the plaintiff does not seek to enforce its patent IN ... by the defendant Emcure Pharmaceuticals Limited at Pune deserves to ...
AstraZeneca Boosts Profit By Axing $800M in Retirement Benefits. By Jim Edwards ... (AZN)'s Q4 earnings got a boost from nearly $800 million in cuts to employees' retirement and pension plans ...
"We believe that the likely worst case for the market incumbents is that the FDA could add additional warnings about increased risk of pancreas-related adverse events" Baum stated in a research note.
This is a classic basal cell carcinoma - the least dangerous form of skin cancer. Note the red color and the almost pearlescent look. These cancers seldom metastasize but can grow larger - and so ...